Description
CD20 (Rituximab Biosimilar) Human mAb was confirmed to bind to its intended target protein CD20 using flow cytometry. CD20 (Rituximab Biosimilar) Human mAb is produced at Cell Signaling Technology. Rituximab is an antibody directed against the extracellular region of human CD20.
Target
CD20
Target Alias Name
MS4A1
Isotype/Mimetic
IgG1 kappa
Animal-Derived Biomaterials Used
BSA
Sequence Available
Yes
Original Discovery Method
Immunization
Antibody/Binder Origins
Animal-dependent discovery, post-2020, In vitro recombinant expression, Animal-derived biomaterials used in production or final formulation